apocell Home Contact Us
  • OVER 175 CLINICAL TRIALS TO DATE


  • contact us
  • News

Illuminating biomarker detection – Leading the way in personalized medicine.

2016

ASCO 2016 Annual Meeting 2016 – Chicago, IL, June 2016

Callisia Clarke, Krittiya Korphaisarn, Zhiqin Jiang, Shadarra Crosby, Darren W. Davis, Weiguo Wu, Kanwal Pratap Singh Raghav, Michael J. Overman, Van Karlyle Morris, Bryan K. Kee, Cathy Eng, David R. Fogelman, Nicholas Navin, Scott Kopetz. “Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer.”  Clin Oncol 34, 2016 (suppl; abstr e23023)

Alpa Manchandia Nick, Geoff Copper, Weiguo Wu, Cherie Dantone, Asifa Haider, Bryan Fellman, Darren W. Davis, Anil Sood “Characterization of CTCs isolated from patients with recurrent ovarian cancer using an antibody-free CTC isolation device”. J Clin Oncol 34, 2016 (suppl; abstr e17056)

Darren W. Davis, Asifa Haider, Valerie Pierron, Fabien Schmidlin .”Apostream to isolate circulating tumor cells (CTC) from castration-resistant prostate cancer patients (CRPC) that express androgen receptor variant 7 (AR-V7) associated with resistance to AR-targeting drugs”.J Clin Oncol 34, 2016 (suppl; abstr e23025)

Bora Lim, Rashmi Murthy, Summer Jackson,Jie Willey, Jangsoon Lee, Ricardo Alvarez , Carlos Barcenas, Nuhad Ibrahim, Meghan Karuturi, Daniel Booser, Stacy Moulder, Sharon Giordano, Abenaa Brewster, Ronald Walters, Powel Brown, Debu Tripathy, Vicente Valero, and Naoto T. Ueno. Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. Poster Board: #97 :June 05: Abstract 609 Poster Session Breast Cancer—HER2/ER

2015

NCI-AACR-EORTC 2015 Molecular Targets and Cancer Therapeutics – Boston, MA, November 2015

Balasubramanian P, et al. “Epithelial and Mesenchymal Phenotypic Characterization and Mutation Detection in Circulating Tumor Cells Isolated from Peripheral Blood of Non-Small Cell Lung Cancer Patients with ApoStream® Technology.”

Tran HT, et al. “The Use of an Antibody Independent Method, ApoStream®, to Isolate Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer Patients and Identification of EGFR Mutations.”

Wang L, et al. “Characterization and Enumeration of Multiple Circulating Tumor Cell Phenotypes Using Two Distinct Platforms Establishes Presence of Epithelial-Mesenchymal Transition in CTCs in Patients.”

ASCO Annual Meeting 2015 – Chicago, IL, May-June 2015

Le Du F, et al. “EpCAM-Independent Isolation of Circulating Tumor Cells with EMT Phenotype in Patients with Primary Breast Cancer Treated with Primary Systemic Therapy.”

American Urology Association Annual Meeting 2015 – New Orleans, LA, May 2015

Gorin MA, et al. “Development of a Novel Method for Detecting Renal Cell Carcinoma Circulating Tumor Cells.”

2014

San Antonio Breast Cancer Symposium 2014 – San Antonio, TX, December 2014

Le Du F, et al. “Predictive Impact of Circulating Tumor Cells with an Epithelial-to-Mesenchymal Transition Phenotype in Patients with Primary Breast Cancer Treated with Primary Systemic Therapy.”

Perez E, et al. “Etirinotecan Pegol Target-Specific Pharmacodynamic Biomarkers in Circulating Tumor Cells from Patients with Metastatic Breast Cancer in the Phase III BEACON Study.”

Perez E, Ueno NT. “Advancements Utilizing Circulating Tumor Cell Technology to Predict Outcomes in Patients with Breast Cancer.” Oral Presentation.

Circulate: Circulating Cancer Biomarkers 2014 – Boston, MA, November 2014

Kinders R. “Validation and Clinical Readiness of the ApoStream for Isolation of Circulating Tumor Cells from Blood Specimens of Patients with Solid Tumors.” Oral Presentation.

ASCO Genitourinary Cancer Symposium 2014 – San Francisco, CA, January 2014

Dinney C, et al. “Characterization of Circulating Tumor Cells Isolated from Bladder Cancer Patients Using ApoStream® Reveals Heterogeneity and Biomarkers of Epithelial-Mesenchymal Transition.”

2013

San Antonio Breast Cancer Symposium 2013 – San Antonio, TX, December 2013

Anderes K, et al. “Subpopulation Heterogeneity Demonstrated in Circulating Tumor Cells Isolated from Breast Cancer Patients Using ApoStream®, an Antibody-Independent Cancer Cell Recovery Device.”

NCI-AACR-EORTC 2013 Molecular Targets and Cancer Therapeutics – Boston, MA, October 2013

Jafferji I, et al. “ApoStream® Isolated Circulating Tumor Cells from Primary Breast Cancer Patients Reveals Heterogeneous Phenotypes Related to Epithelial-Mesenchymal Transition and Stem Cell Markers.”

Roarty E, et al. “Characterization and Identification of Specific EGFR Mutations in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer Patients Using an Antibody Independent Method, ApoStream®: An Update Report.”

ECCO-ESMO-ESTRO 2013 – Amsterdam, The Netherlands, September-October 2013

Varadhachary G, et al. “Molecular Characterization of Circulating Tumor Cells Recovered From Metastatic Pancreatic Cancer Patients by ApoStream®, a New Antibody-Independent Dielectrophoretic Device.”

2013 ASCO Annual Meeting – Chicago, May-June 2013

Hoch U, et al. “Etirinotecan pegol Target-Specific Pharmacodynamic (PD) Biomarkers Measured in Circulating Tumor Cells (CTCs) from Patients in the Phase 3 BEACON Study in Patients with Metastatic Breast Cancer (mBC).”

Tran HT, et al. “Characterization and Identification of Specific EGFR Mutations in Circulating Tumor Cells (CTCs) Isolated From Non-Small Cell Lung Cancer Patients Using an Antibody Independent Method, ApoStream®.”

Advanced Microfluidics and Nanofluidics 2013 – Dielectrophoresis Special Session

Menachery A. “ApoStream® from Concept to Market.” Oral Presentation.

Menachery A. “ApoStream®, a New Dielectrophoretic Device for Antibody Independent Isolation and Recovery of Viable Cancer Cells from Blood.” Oral Presentation.

AACR Annual Meeting 2013

Varadhachary G, et al. “ApoStream®, a New Dielectrophoretic Device for Antibody-Independent Isolation and Recovery of Circulating Tumor Cells From Blood of Patients With Metastatic Pancreatic Adenocarcinoma.”

Molecular Medicine Tri Conference

Poklepovic A. “Utilization of Dielectrophoresis for Antigen Independent Circulating Tumor Cell (CTC) Capture Allows for Detection of Heterogeneous Tumor Cell Populations.” Oral Presentation.

2012

NCI-AACR-EORTC Molecular Targets and Cancer Therapeutics, Dublin, Ireland, November 2012

Neal C, et al. “Expanded Phenotypic and Biological Characterization of Rare Cells Isolated From Prostate, NSCLC, and Pancreatic Cancer Patient Blood Using ApoStream®.”

Poklepovic A, et al. “Comparison of Dielectrophoretic Field Flow Fractionation (DEP-FFF) with ApoStream®, an Antibody Independent Platform, with Immunomagnetic Capture using CellSearch for Enumeration of Circulating Tumor Cells in Patients with Metastatic Prostate Cancer.”

ESMO 2012 – Vienna, Austria, September-October 2012

Amato R, et al. “Improved Enumeration of Circulating Tumor Cells and Correlation With Clinical Endpoints in Castration-Resistant Prostate Cancer Patients.”

ADAPT Congress 2012 – Washington, D.C., September 2012

Gupta V, et al. “ApoStream®, a Novel Device for Antibody-independent Capture of Circulating Tumor Cells (CTCs) from Blood of Patients with Various Types of Cancer.”

Biomarker World Congress – Philadelphia, PA, May 2012

Gupta V, et al. “Performance of a New Generation Antibody-Independent ApoStream® Platform for the Enrichment of Circulating Tumor Cells (CTCs).”

AACR – Chicago, IL March-April 2012

Gupta V, et al. “Performance of a New Generation Antibody-Independent ApoStream® Platform for the Enrichment of Circulating Tumor Cells (CTCs).”

Poklepovic A, et al. “ApoStream®, an Antibody Independent Platform, Captures Circulating Tumor Cells in Patients with Hepatocellular Carcinoma.”

Molecular Medicine Tri-Conference – San Francisco, CA February 2012

Gupta V, et al. “ApoStream®, a Novel Device for Antibody-Independent Capture of Circulating Tumor Cells from Blood of Patients with Various Types of Cancer.”

2011

EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics – San Francisco, CA November 2011

Gupta V, et al. “EpCAM-Independent ApoStream® Technology Isolates Circulating Tumor Cells from Blood of Patients with Various Types of Cancer.”

Neal C, et al. “Measurement of CUDC-101 Target Inhibition in Circulating Tumor Cells Using a Fluorescent-Based, Quantitative Assay

EORTC/NCI/ASCO Molecular Markers in Cancer – Brussels, Belgium October 2011

Gupta V, et al. “Antibody-Independent Enrichment of Live Circulating Tumor Cells (CTCs) from a Variety of Cancer Types.”

CHI’s ADAPT Conference – Philadelphia, PA September 2011

Melnikova V, et al. “Development of Allele-Specific PCR Assay for Detection of BRAF V600E Mutation in Circulating Tumor Cells.”

Gupta V, et al. “Antibody-Independent Enrichment of Live Circulating Tumor Cells (CTCs) from a Variety of Cancer Types.”

AACR – Orlando, FL April 2011

Abstract #3159, Melnikova VO et. Al., “BRAFV600E mutation analysis in circulating tumor cells.”

Abstract #4155, Wu W, et. Al.,“Simultaneous Quantification of Multiple Signaling Molecules in Individual Circulating Tumor Cells (CTCs) by Multi-Color Laser Scanning Cytometry.”

Biomarker Assay Development – San Diego, CA 2011

Melnikova VO et. Al.,“BRAF V600E Mutation Allele- Specific PCR Assay in Circulating Tumor Cells.”

High Content Analysis – San Francisco, CA 2011

Wu W, A et. Al., “High Content Imaging and Characterization of Circulating Tumor Cells (CTC) from Cancer Patients.”

2010

EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics – Berlin, Germany November 2010

Davis, DW et. Al.,“Molecular Characterization of Circulating Tumor Cells Using a Highly Sensitive Method of Enrichment Based on the CellSearch CTC Profile Kit.”

ESMO 2010 – Milan, Italy October 2010

Abstract #1335P, Eisen, A et. Al., “CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potent MEK1 Inhibitor, For Treatment Of BRAF-Mutated Melanoma.”

ASCO – Chicago, Illinois June 2010

Abstract #3093, Davis, DW et. Al., “Sensitive Detection of Gamma-H2AX Induction as a Pharmacodynamic Marker for Profiling Patients With Cancer Treated With Topotecan.”

Abstract #3040, Martin SF et. Al., “Treatment of VHL Patients With Sunitinib: Clinical Outcomes and Translational Studies.”

AACR – Washington, D.C. April 2010

Abstract # 2687, Melnikova VO et. Al., “Development of a New, Highly Sensitive Assay for Circulating Tumor Cell (CTC) Detection Based on the CellSearch® CTC Profile Kit Enrichment and Laser Scanning Cytometry Analysis”

2009

ASCO – Orlando, Florida May 2009

Abstract #3525, Davis, DW et. Al., “Circulating Tumor and Endothelial Cells as Pharmacodynamic Biomarkers in a Phase I Clinical Trial of Intravenous Bevacizumab in Combination with Escalating Doses of Oral Cediranib for Patients with Advanced Malignancies”

EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics – Boston, Massachusetts November 2009

Davis, DW et. Al., “Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial”

Abstract #7534, Davis, DW et. Al., “Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies.”

2007

ASCO – Chicago, Illinois May 2007

Abstract #8021, Davis, DW, et. al., “pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer”

EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics San Francisco, CA 2007

Abstract #C165, Davis, DW et. al.,”Predictive Markers of Response in a Phase I/II Pharmacodynamic (PD) Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer (HNC)”.

2006

EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics – Prague, Czech Republic 2006

Abstract #57, Davis, DW et. al., “Correlation of Receptor Tyrosine Kinase (RTK) Activity and Apoptosis With Response to Sunitinib Treatment in Patients With Gastrointestinal Stromal Tumor (GIST)”.

ICACT Paris, France 2006

Abstract #A300, Davis, DW et. al., “Receptor Tyrosine Kinase Activity and Apoptosis as Biomarkers of SU11248 (Sunitinib Malate) Activity in Patients With Gastrointestinal Stromal Tumor”.

2005

EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics – Philadelphia, Pennsylvania 2005

Davis, DW, et. al., Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy.

ECCO Paris, France 2005

Abstract # 715, Davis, DW, et. al., Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumours: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy. Oral Presentation.

ASCO – Orlando, Florida, May 2005

Abstract #3006, Davis, DW, et. al., “Pharmacodynamic Analysis of Target Receptor Tyrosine Kinase Activity and Apoptosis in GIST Responding to Therapy with SU11248”.

Abstract #9001, Trent JC, et. al., “Antivascular and Apoptotic Effects of Imatinib in GIST”.